| アイテムタイプ |
紀要論文 / departmental bulletin paper(1) |
| 公開日 |
2024-06-20 |
| タイトル |
|
|
タイトル |
Long-Term Clinical Outcomes of the Patients with Chronic Myeloid Leukemia Treated with Nilotinib as the 1st-Line Tyrosine Kinases Inhibitor at the Kindai university hospital |
|
言語 |
en |
| 作成者 |
Hirase, Chikara
Matsumura, Itaru
Kumode, Takahiro
Serizawa, Kentaro
Morita, Yasuyoshi
Tanaka, Hirokazu
Fukuoka, Kazuya
|
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
chronic myeloid leukemia, molecular targeted therapies, nilotinib, outcome assessment |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Nilotinib has been shown to be a more potent tyrosine kinase inhibitor of BCR::ABL1 than imatinib. We evaluated long-term efficacy and safety based on the 7-year follow-up data in patients with newly diagnosed chronic myeloid leukemia (CML) who were treated with nilotinib as the 1st-line therapy (1L-NIL) at the Kindai university hospital.
Methods: In this single-center, observational study, we enrolled patients with newly diagnosed CML in chronic phase (CML-CP) who received 1L-NIL since December 2010, when nilotinib received regulatory approval for CML-CP in Japan. The primary endpoint was overall survival (OS) of the 1L-NIL patients. In addition, we analyzed molecular responses and safety profiles as the key secondary endpoints.
Results: The median observation period was 6.8 (range: 1.2-12.3) years. The estimated OS and progression-free survival rates of the 1L-NIL patients (n=25) were both 95.5%. By 18 months, the cumulative achievement rates of major molecular response (MMR) and MR4.5 were 81.3% and 25.0%, respectively. Adverse events (AEs) occurred in 21 of 23 patients (91.3%) with Grade ≥3 in 8 of 23 patients (34.8%). We observed no unexpected serious AEs in this research.
Conclusions: Our data showed that the efficacy of nilotinib persisted over the 7-year follow-up and long-term administration of nilotinib was not associated with unacceptable late toxic effects at the Kindai university hospital. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
The Kindai University Medical Association |
|
言語 |
en |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| ID登録 |
|
|
ID登録 |
10.15100/0002001137 |
|
ID登録タイプ |
JaLC |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
03866092 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
24327166 |
| 書誌情報 |
en : ACTA MEDICA KINDAI UNIVERSITY
巻 49,
号 1,
p. 15-25,
発行日 2024-06
|
AA0050842X-20240600-0015.pdf
